MedPath

Novartis Pharma Schweiz AG

🇨🇭Switzerland
Ownership
Subsidiary
Employees
-
Market Cap
-
Website

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

106

NMPA:92
SFDA:14

Drug Approvals

Brolucizumab Injection

Product Name
倍优适
Approval Number
国药准字SJ20250020
Approval Date
May 27, 2025
NMPA

Brolucizumab Injection

Product Name
倍优适
Approval Number
国药准字SJ20250019
Approval Date
May 27, 2025
NMPA

Asciminib Hydrochloride Tablets

Product Name
信倍立
Approval Number
国药准字HJ20250056
Approval Date
May 13, 2025
NMPA

Siponimod Tablets

Product Name
万立能
Approval Number
国药准字HJ20200010
Approval Date
Nov 20, 2024
NMPA

Siponimod Tablets

Product Name
万立能
Approval Number
国药准字HJ20200011
Approval Date
Nov 20, 2024
NMPA

Deferasirox Dispersible Tablets

Product Name
恩瑞格
Approval Number
国药准字HJ20150208
Approval Date
Aug 22, 2024
NMPA

Ciclosporin Injection

Product Name
山地明
Approval Number
国药准字HJ20150095
Approval Date
Jun 27, 2024
NMPA

Capmatinib Hydrochloride Tablets

Product Name
妥瑞达
Approval Number
国药准字HJ20240041
Approval Date
Jun 11, 2024
NMPA

Capmatinib Hydrochloride Tablets

Product Name
妥瑞达
Approval Number
国药准字HJ20240042
Approval Date
Jun 11, 2024
NMPA

Iptacopan Hydrochloride Capsules

Product Name
飞赫达
Approval Number
国药准字HJ20240016
Approval Date
Apr 24, 2024
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 10
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.